Levofloxacin in the Medical Management of Community-acquired Pneumonia (Interview with Prof. Andy I. M. Hoepelman)

20 June, 2018


drphoto    name



CAP – Defining the Diagnosis
Q01 Definition and diagnosis of community-acquired pneumonia (CAP)
Q02 Investigating the CAP patient – what is required?
Q03 Risk factors for a poor prognosis


The Pathogens Responsible for CAP and their Antimicrobial Susceptibility
Q04 Bacterial etiology of CAP
Q05 The role of atypicals in CAP
Q06 Predicting the pathogen in CAP based on severity of disease
Q07 Which antimicrobials should be used in CAP?
Q08 Resistance in respiratory tract infections: the incidence of penicillin-resistant Streptococcus pneumoniae (PRSP) in Europe
Q09 Macrolide resistance – how has it changed CAP therapy?


Pharmacokinetic Features of Fluoroquinolones
Q10 Major changes in empiric management of CAP
Q11 Predicting fluoroquinolone activity based on pharmacodynamic features
Q12 Pharmacokinetic/pharmacodynamic variables for respiratory fluoroquinolones against Streptococcus pneumoniae


International Society Guidelines for the Management of CAP
Q13 International guidelines for outpatient treatment of CAP – European Respiratory Society (ERS), Infectious Diseases Society of America (IDSA), Canadian Infectious Disease Society/Canadian Thoracic Society (CIDS/CTS)
Q14 International guidelines for outpatient treatment of CAP – Center for Disease Control and Prevention (CDCP), American Thoracic Society (ATS)
Q15 International guidelines for inpatient treatment of CAP – ERS, IDSA, CIDS/CTS
Q16 International guidelines for inpatient treatment of CAP – ATS, CDCP


Levofloxacin – Preeminent Respiratory Fluoroquinolone
Q17 Clinical trials of levofloxacin in CAP
Q18 Levofloxacin versus azithromycin/ceftriaxone in CAP
Q19 Safety of levofloxacin compared to other fluoroquinolones
Q20 Cost-effectiveness data for levofloxacin in CAP